Table 1: Main targeted therapies currently in use for the treatment of medullary thyroid cancer.

Key targetshttp://www.clinicaltrials.gov/
Drug name IC50 RET
M *
RETEGFRVEGFRsPDGFRcKITFGFRMETBRAFOtherDrugs in combinationStatus
identifier (phase)

Vandetanib
(ZD6474)
0.1 BortezomibNot yet recruiting:
NCT01661179 ( )
Recruiting:
NCT00514046 ( )
NCT01496313 (4)
Active, not recruiting, has results:
NCT00410761 (3)
NCT00358956 (2)
NCT00098345 (2)
Active, not recruiting:
NCT000923247 ( )
NCT01298323 (3)
Withdrawn:
DocetaxelNCT000937417
XL184
(Cabozantinib)
0.004Active, not recruiting:
NCT00704730 (3)
NCT00215605 (1)
Available:
NCT01683110
Main TKIsSorafenib (BAY-43-9006)0.0059–0.05Active, not recruiting:
NCT00390325 (2)
Unknown**:
NCT006542387 (2)
Sunitinib (SU11248)0.22–1.3Active, not recruiting:
NCT00381641 (2)
NCT00519896 (2)
NCT00510640 (2)
Motesanib
(AMG-706)
0.05–0.09Completed:
NCT00121628 (2)
Imatinib
(STI571)
5–37 Xeloda, DacarbazineActive, not recruiting:
NCT00354523 ( )

Everolimus (RAD001)mTOR
Pasireotide
Pasireotide
Recruiting:
NCT01625520 (2)
NCT01270321 (2)
NCT01164176 (2)
Unknown**:
NCT0111865 (2)
Main Non-TKIsBortezomib
(PS-341)
proteosome VandetanibActive, not recruiting:
NCT00923247 ( )
Pasireotide
(SOM230)
sst1, 3, 5
(somatostatin receptors)
Everolimus
Everolimus
Recruiting:
NCT01625520 (2)
NCT01270321 (2)

 *IC50 RET [ M]: 50% inhibitory concentration.
**Status has not been verified in more than two years.